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An Uneven Path Forward
The History of Methylmercury Toxicity Research
Organic mercury compounds were first described in the 1800s, with 
fatal cases of methylmercury poisoning reported in 1865. Early reports 
described a distinct set of symptoms of methylmercury toxicity, includ-
ing altered sensation in the face and extremities, tunnel vision, deaf-
ness, loss of coordination, and impaired speech. Nearly a century later, 
against a backdrop of widespread environmental contamination, the 
clinical picture reappeared, and suspicions of additional harm to human 
health had developed. Yet it wasn’t until 2009 that international agree-
ment to control mercury pollution was reached. A historical review 
suggests that—as one early commenter observed—the tunnel vision, 
forgetfulness, and lack of coordination that symptomize methylmercury 
toxicity can also affect the conduct and interpretation of environmental 
health research [EHP 118(8):1137–1145; Grandjean et al.].
Methylmercury became commercially important as a crop fungi-
cide around 1914. Worldwide use was accompanied by worker poison-
ings and several large-scale food poisoning incidents. The compound 
emerged as an industrial pollutant in the early 1950s around Japan’s 
Minamata Bay, where contaminated seafood induced neurologic symp-
toms mirroring those reported in 1865. Epidemiologic evidence from 
Minamata, paired with a 1952 report from Sweden, indicated more 
severe disease from prenatal and early-life exposures, with symptoms 
including mental retardation, seizures, and impaired motor develop-
ment. In the 1960s, advances in analytical technology permitted 
chemical analysis of mercury species in environmental samples, result-
ing in the discovery of methylmercury biomagnification in the food 
chain and identification of environmental methylation of inorganic 
mercury in waterways. Methylmercury had become a worldwide prob-
lem, not simply a local issue.
Defining the scope of the problem, much less acting to address it, 
has involved a political, legal, and ethical maze set on an ever-evolving 
and still-incomplete scientific foundation. Initially, the inability to iden-
tify mercury species in the environment hampered researchers’ efforts 
to link the presence of methylmercury with poisoning symptoms. That 
link also was blurred by a time lag of weeks to months between exposure 
and initial symptoms as well as slow recognition of the significance of 
experimental and wildlife data. Industrial suppression of toxicity data 
impaired accurate risk assessment, as did imprecise estimates of expo-
sure, delayed recognition of low-dose effects, and use of adult data only.
Consequently, regulatory safeguards established in the 1960s and 
1970s are now known to be inadequate, but improvements have been 
deferred in light of scientific uncertainties. For example, although it 
remains unknown whether a “safe” threshold exists for prenatal and 
early-life exposure to methylmercury, evidence of methylmercury 
damage to neurodevelopment has been accumulating since the 1950s. 
More research is certainly needed, the authors write, but prevention 
and correction of environmental health problems need not and should 
not be delayed by a desire for absolute proof.
Julia R. Barrett, MS, ELS, a Madison, WI–based science writer and editor, has written for 
EHP since 1996. She is a member of the National Association of Science Writers and the Board of 
Editors in the Life Sciences.
Breaking Patterns of Disease
Early-Life Clues May Predict Long-Term Health
Modern diseases often seem to occur in isolation, but many are 
now known to emerge from a complex web or pattern of conditions 
linked together by certain underlying biological mechanisms and 
processes. With the help of large disease databases, medical scientists 
have begun to discern how such patterns occur over the course of a 
lifetime. A new review focused on developmental immuno  toxicology 
explores how this integrative perspective might inspire novel strate-
gies for lowering the risk and prevalence of immune-based dis-
eases influenced by environmental stimuli [EHP 118(8):1091–1099; 
Dietert et al.].
Many chronic diseases share three common features: 1) early-life 
exposures to chemical agents or pathogens, 2) evidence of immune 
insult or dysfunction, and 3) the appearance of disease biomarkers in 
exposed children although disease itself may not manifest until later 
in life. One example of interlinked disease conditions highlighted by 
the authors is metabolic syndrome, defined as the co-occurrence of 
at least three of five conditions: insulin resistance, obesity, high blood 
pressure, elevated triglycerides, and reduced HDL cholesterol. 
Immune dysfunction is central to the underlying physiology of 
metabolic syndrome, and the authors posit that the seeds of such 
dysfunction may be planted in childhood. They describe pre- and 
postnatal exposures to environmental risk factors that produce post-
natal lipid dysregulation and immune dysfunction. However, it is 
not yet known whether immune dysfunction is an underlying cause 
of metabolic syndrome or simply an associated or disease-facilitating 
characteristic.
The practical key to preventing metabolic syndrome may lie in 
treatments that address overall patterns and their progression, not just 
the initial presenting condition. “For those patterns of disease with 
immune involvement,” the authors write, “preventing the underlying 
immune dysfunction is the single most effective option to minimize 
the risk of one or more chronic diseases later in life.” This will require 
more information about risk factors for immune dysfunction that 
are encountered during development or childhood. Therefore, the 
authors also recommend that chemicals and pharmaceuticals be tested 
for developmental immunotoxicity end points; currently, safety assess-
ments are based solely on adult exposures. 
The authors say patterns of disease can be used to better predict, 
prevent, and treat diseases associated with an immune-related pattern 
of diseases, and may also serve as the basis for environmental protection 
and testing to prevent exposure to developmental immunotoxicants that 
may contribute to multiple interconnected diseases. But pattern-based 
evaluation, prevention, and treatment will require a shift from the pre-
vailing single-organ approach to disease classification and management.  
M. Nathaniel Mead, a science writer living in Durham, NC, has written for EHP since 2002.
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Environmental Health Research Model 
Combines Toxicology and Infectious Disease
Although pathogens are known to modify the effects of toxicants, 
U.S. environmental health research currently focuses on phys-
ical agents and chemical toxicants—a focus that limits the field 
by ignoring the interaction between pathogens and toxic agents 
[EHP 118(8):1165–1172; Feingold et al.]. These authors present a con-
ceptual paradigm that integrates 
infectious disease and toxicologic 
environmental health research, 
promotes cross-disciplinary edu-
cation and communication, and 
elucidates a fuller body of environ-
mental health risk factors.
Chemical  toxicity  often 
involves relatively direct effects 
of exposures on health outcomes, 
but infectious disease transmission 
typically is more complex, depend-
ing on factors such as dynamic 
environmental and ecologic sys-
tems, patterns of contact among 
populations, and host immune 
status. But interactions between 
pathogens and toxicants are unde-
niable. For instance, hepatitis B 
virus and aflatoxin individually 
increase the risk of liver cancer, but 
combined exposure to both agents 
increases risk far more than would 
be expected based on effects of the two risk factors in isolation. And in 
the case of cervical cancer, although infection with human papilloma-
virus is believed to be necessary for the cancer to occur, smoking may 
act as a cofactor and increase the risk the cancer will occur in someone 
infected with the virus.
The authors identify multiple points between initial exposure and 
clinical disease at which toxicant–pathogen interactions can occur. They 
also describe approaches common to both areas of research. Both focus 
on upstream interventions to prevent disease by preventing exposure. 
Both areas also focus on spatial context (i.e., proximity to toxic or 
pathogenic agents) and quantitative 
modeling to estimate exposure, and 
both use biomarkers to study expo-
sure, susceptibility, and disease.
Fostering  collaborations 
between researchers in these fields 
can lead to a better understanding 
of complex exposures and resulting 
diseases. “Classic reductionist think-
ing in toxicology focuses on ‘one 
toxicant, one outcome’ research,” 
the authors write. In contrast, 
they conclude, “If basic research 
is to increase our ability to predict 
the consequences of exposure to 
environmental chemicals, we must 
embrace nonreductionist thinking 
and design experimental models 
that emulate human experience.”
Harvey Black of Madison, WI, has written for 
EHP since 1994. His work has also appeared 
in  Environmental  Science  &  Technology, 
ChemMatters, and the Milwaukee Journal 
Sentinel.
Body of Proof
Biomonitoring Data Reveal Widespread 
Bisphenol A Exposures
A review of more than 80 biomonitoring studies from nine nations 
suggests exposure to bisphenol A (BPA) is ubiquitous in people 
throughout the world [EHP 118(8):1055–1070; Vandenberg et al.]. 
Moreover, in samples of blood serum, median levels of unconju-
gated (biologically active) BPA were higher than levels predicted by 
toxicokinetic models that form the basis of U.S. regulations for the 
compound, reaching the range that has been shown to cause adverse 
effects in animals. 
More than 8 billion pounds of BPA are produced each year, 
making it one of the world’s most heavily used chemicals. BPA is used 
in baby bottles, drinking bottles, food storage containers, polyvinyl 
chloride, stretch films, paper, cardboard, medical equipment, and 
the epoxy resins lining most metallic food and beverage cans. BPA 
has estrogenic properties, and animal studies have linked low-level 
exposure to altered development of the male and female reproductive 
tract and brain as well as cancers of the mammary gland and prostate.
The authors analyzed 24 biomonitoring studies involving blood 
serum samples from healthy adults, adults with certain diseases, preg-
nant women, and fetuses or fetal tissues. Overall, these studies indicate 
exposure to unconjugated BPA is in the range of 0.5–10 ng/mL, with 
most studies suggesting an average exposure of 1–3 ng/mL. The latter 
concentrations are higher than those shown to cause effects in human 
and animal cell cultures.
The only data on BPA levels in children after birth is from studies of 
urine samples, most of which measured total (conjugated and unconju-
gated) BPA, but some of which measured unconjugated BPA separately 
from conjugated (inactive) BPA. The Centers for Disease Control and 
Prevention measured total BPA in urine samples from 314 children aged 
6–11 years and 715 adolescents aged 12–19. Compared with adults, the 
younger children’s levels were highest, and adolescents were in-between. 
Other smaller studies also showed that BPA concentrations were higher in 
neonates and young children than in adults.
Some of the studies measuring BPA in human blood were conducted 
using the enzyme-linked immunosorbent assay. Although this assay is 
considered less specific than the more precise analytical chemistry methods 
now favored for measuring BPA, the authors argue these studies are 
worthy of inclusion in their review because the concentrations they report 
are in line with what have been detected using the newer methods. 
The paper also points out “significant deficiencies” in the two studies 
that have examined the toxicokinetics of BPA exposure in humans, 
which they say have been given undue weight in regulatory decision 
making. The authors note we don’t yet know all the potential sources 
of exposure to BPA, which makes it impossible to predict toxicokinetics. 
Because the biomonitoring findings contradict the toxicokinetic studies, 
the authors recommend in a related commentary in the same issue 
[EHP 118(8):1051–1054; Vandenberg et al.] that biomonitoring data be 
considered in regulatory decision making whenever available rather than 
relying only on toxicokinetic models to estimate exposure.
Kellyn S. Betts has written about environmental contaminants, hazards, and technology for 
solving environmental problems for publications including EHP and Environmental Science & 
Technology for more than a dozen years.
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Pathogen–toxicant inter  actions may influence the progression from 
exposure to disease at multiple points.
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